300 related articles for article (PubMed ID: 33549137)
1. Analysis of patient access to orphan drugs in Turkey.
Koçkaya G; Atalay S; Oğuzhan G; Kurnaz M; Ökçün S; Sar Gedik Ç; Şaylan M; Şencan N
Orphanet J Rare Dis; 2021 Feb; 16(1):68. PubMed ID: 33549137
[TBL] [Abstract][Full Text] [Related]
2. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
3. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
[TBL] [Abstract][Full Text] [Related]
4. An Overview of the Orphan Medicines Market in Turkey.
Koçkaya G; Wertheimer AI; Kilic P; Tanyeri P; Mert Vural I; Akbulat A; Artiran G; Kerman S
Value Health Reg Issues; 2014 Sep; 4():47-52. PubMed ID: 29702806
[TBL] [Abstract][Full Text] [Related]
5. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
6. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
7. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
8. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
Vokinger KN; Kesselheim AS
BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of the evolution in the access to orphan medicines in Spain].
Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
[TBL] [Abstract][Full Text] [Related]
10. Critical assessment of belgian reimbursement dossiers of orphan drugs.
Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
[TBL] [Abstract][Full Text] [Related]
11. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
12. Determinants of orphan drugs prices in France: a regression analysis.
Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
[TBL] [Abstract][Full Text] [Related]
13. Uptake of orphan drugs in the WHO essential medicines lists.
Costa E; Moja L; Wirtz VJ; van den Ham HA; Huttner B; Magrini N; Leufkens HG
Bull World Health Organ; 2024 Jan; 102(1):22-31. PubMed ID: 38164340
[TBL] [Abstract][Full Text] [Related]
14. Orphan drugs for rare diseases: is it time to revisit their special market access status?
Simoens S; Cassiman D; Dooms M; Picavet E
Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
[TBL] [Abstract][Full Text] [Related]
15. [Access to medicines for rare diseases: regulatory aspects and public health priorities.].
Costa E; Grimaldi G; Del Grosso V; Isgrò A; Genazzani A
Recenti Prog Med; 2022; 113(7):415-424. PubMed ID: 35852076
[TBL] [Abstract][Full Text] [Related]
16. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
17. No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.
Stolk P; Heemstra HE; Leufkens HG; Bloechl-Daum B; Heerdink ER
Orphanet J Rare Dis; 2009 Dec; 4():27. PubMed ID: 20003427
[TBL] [Abstract][Full Text] [Related]
18. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Heard JM; Vrinten C; Schlander M; Bellettato CM; van Lingen C; Scarpa M;
Orphanet J Rare Dis; 2020 Jan; 15(1):3. PubMed ID: 31907071
[TBL] [Abstract][Full Text] [Related]
19. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
20. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
Döring JH; Lampert A; Hoffmann GF; Ries M
PLoS One; 2016; 11(8):e0161660. PubMed ID: 27557111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
